



Cindy Arteta (1,2), Rodolfo Villena (1,3), María Elena Santolaya (1,2)

1. Faculty of Medicine Universidad de Chile, 2. Hospital de niños Dr Luis Calvo Mackenna 3. Hospital de

niños Dr Exequiel González Cortés





Contact: Rodolfo Villena. rvillena@uchile.cl

november 2021







## Introduction

- "Defeating meningitis by 2030" is a goal of the World Health Organization
- To address the sequelae is one of the pillar for it
- Chilean study: overall IMD sequelae rate of 28% (MenB outbreak in 90s)

## Objective

• Describe the sequelae caused by IMD in pediatric patients

## Methods

- Cross-sectional study performed with medical records in two pediatric public hospitals in Santiago, Chile
- Patients with diagnosis of IMD from 2009-2019 microbiologically confirmed were included
- Bivariate analysis and logistic regression were performed





Results

#### "Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019"



Table 1. Socio-demographic data of children with IMD, Chile, 2009-2019

Variables		Total n=49 (%)	Sequelae n=29 (%)	No sequelae n=20 (%)	p value	
			59%			
Age	Median [IQR], months	9 [4-27]	8.0 [4-23]	12.0 [4-82]		_
	< 1 year old	28 (57.1)	18 (62.0)	10 (50.0)	0.40	79,5%
	1-4 years old	11 (22.4)	7 (24.1)	4 (20.0)	0.74	Γ , 5,570
	<u>&gt;</u> 5 years old	10 (20.4)	4 (13.7)	6 (30.0)	0.14	
Gender	Male	34 (69.3)	19 (65.5)	15 (75.0)	0.45	
Socioeconomic	High	1 (2.0)	1 (3.4)	0	0.40	
status	Middle	26 (53.0)	12 (41.3)	14 (70.0)	0.04	0.00/
	Low	22 (44.9)	16 (55.1)	6 (30.0)	0.08	<b>98%</b>
Comorbidity	Yes	16 (32.6)	9 (31.0)	7 (35.0)	0.76	
Type of	Recurrent wheezing	9 (18.3)	5 (17.2)	4 (20.0)	0.78	
comorbidity	Immunodeficiency	2 (4.0)	1 (3.4)	1 (5.0)	0.78	
	Prematurity	2 (4.0)	2 (6.9)	0	0.26	
	Neurological disease	1 (2.0)	0	1 (5.0)	0.22	
	Congenital cardiopathy	1 (2.0)	0	1 (5.0)	0.22	
	Obesity	4 (8.1)	3 (10.3)	1 (5.0)	0.52	Menin
	Malnutrition	2 (4.0)	1 (3.4)	1 (5.0)	0.78	Menin Resea Found





Table 2. Clinical characteristics of invasive meningococcal disease by presents of sequelae in Chilean children during 2009-2019

Univariate Associations						Logistic Regression analysis		
Va	ariable	Total N 49 (%)	Sequelae N 29	No sequelae 20	p value	OR	95% CI	
			(%)	(%)				
Onset of	Median [IQR]	2.0 [1.0-4.0]	2.0 [1.0-3.0]	2.0 [1.0-3.0]	1	-	-	
symptoms before	2							
consulting (days								
Number of	F 1	11 (22.4)	8 (27.5)	3 (15.0)	0.31			
medical visits	2	27 (55.1)	15 (51.7)	12 (60.0)	0.56			
	<u>&gt;</u> 3	11 (22.4)	6 (20.6)	5 (25.0)	0.67			
Signs and	Fever	49 (100)	29 (100)	20 (100)	1			
symptoms	Compromised general	36 (73.4)	23 (79.3)	13 (65.0)	0.26	0.28	(0.03 – 2.56)	
	condition							
Results	Shock	25 (51.0)	8 (27.5)	3 (15.0)	0.03	2.15	(0.49 – 9.41)	
nesures	Vomiting	31 (63.2)	16 (55.1)	15 (75.0)	0.01	17.06	(1.74 – 166.94)	
	Diarrhea	14 (28.5)	8 (27.5)	6 (30.0)	0.84	1.62	(0.23 – 11.40)	
	Abdominal pain	6 (12.2)	2 (6.9)	4 (20.0)	0.16	0.29	(0.04 - 1.80)	
Meningitis Research Foundation	Drowsiness/irritability	23 (46.9)	17 (58.6)	7 (35.0)	0.10	2.83	(0.39 – 20.44)	
	Meningeal signs	21 (42.8)	17 (58.6)	4 (20.0)	0.007	0.04	(0.00 – 0.55)	
	Neurological deficit	20 (40.8)	16 (55.1)	4 (20.0)	0.2	0.34	(0.07 – 1.56)	
	Headache	14 (28.5)	10 (34.4)	4 (20.0)	0.27	1.09	(0.16 – 7.28)	
	Seizures	3 (6.1)	2 (6.9)	1 (5.0)	0.78	-	-	
	Petechiae/rash	20 (40.8)	12 (41.3)	8 (40.0)	0.92	0.66	(0.12 – 3.48)	





Table 2. Clinical characteristics of invasive meningococcal disease by presents of sequelae in Chilean children during 2009-2019

Univariate Associations					Logistic Regression analysis		
Variable		Total N 49 (%)	Sequelae N 29 (%)	No sequelae 20 (%)	P value	OR	95% CI
Clinical diagnosis	Meningitis + meningococcemia	19 (38.7)	17 (58.6)	2 (10.0)	<0.001	12.75	(2.48 – 65.54)
	Bacteremia	10 (20.4)	1 (3.4)	9 (45.0)	<0.001	0.007	(0.00 - 0.21)
	Septic arthritis	7 (14.2)	7 (24.1)	0	0.01		
	Meningitis	6 (12.2)	2 (6.9)	4 (20.0)	0.16	3.64	(0.31 – 41.65)
	Meningococcemia	5 (10.2)	0	5 (25.0)	0.06	-	-
	Waterhouse	2 (4.0)	2 (6.9)	0	0.23	-	-
	Friderichsen Syndrome						
Number of sequelae	1	19 (38.7)	19 (65.5)	-			
	2	8 (16.3)	8 (27.5)	-			
	3	2 (4.0)	2 (6.9)	-			
Type of sequelae*	Neurological disorders	19 (38.7)	19 (65.5)	-			
	Hearing loss	10 (20.0)	10 (34.4)	-			
Meningitis Research	Osteoarticular	9 (18.3)	9 (31.0)	-			
Foundation	Skin scarring	3 (6.1)	3 (10.3)	-			
Post discharge	Yes	34 (69)	27 (93.1)	7 (35.0)	<0.001		
follow-up							
N. meningitidis	В	17 (34.6)	11 (37.9)	6 (30.0)	0.61		
serogroup	W	30 (61.2)	16 (55.1)	14 (70.0)	0.29		






Table 3. Classification of sequelae in children with IMD

Type of sequelae	Number of sequelae: 54	%
Neurological disorders	32	59.2
Psychomotor developmental	12	22.2
delay		
Speech-language	7	12.9
impairment		
Seizures	5	9.2
Hypertonia/Hypotonia	5	9.2
Nerve damage	2	3.7
Attention deficit/	1	1.8
hyperactivity disorder		
Hearing loss	10	18.5
Cochlear implan <b>t</b>	2	3.7
Skin scarring	3	5.5
Osteoarticular	9	16.6
Movement limitation	6	11.1
Surgical debridement	2	3.7
Amputation	1	1.8

Figure 1. Sequelae of meningococcal disease by serogroup in chilean children, 2009-2019










### Sequelae by serogroup and time interval in peadiatrics \* patients, Chile 2009-2019







#### Conclusions

- Invasive meningococcal disease remains as a public health concern
- A high rate of sequelae were found in pediatric patients in Chile (59%)
  - Focus in < 1 yoa, shock and meningeal signs at admission
  - Clinical manifestations: meningitis + meningococcemia
  - Neurological sequelae were the most prevalent
- A multidisciplinary follow-up protocols to reduce their long-term impact must be urgently established as a priority to assess all children and their families with the aim to reduce the long-term consequences/impact of IMD







Cindy Arteta (1,2), Rodolfo Villena (1,3), María Elena Santolaya (1,2)

1. Faculty of Medicine Universidad de Chile, 2. Hospital de niños Dr Luis Calvo Mackenna 3. Hospital de

niños Dr Exequiel González Cortés





Hospital de Niños Dr. Luis Calvo Mackenna spital Autogestionado en Red de Alta Complejidi Fundado en 1942

november 2021

Contact: Rodolfo Villena. rvillena@uchile.cl